Logo

A Positive Trial

Apr 28, 2010

Genentech's Lucentis helps prevent vision loss due to diabetic macular edema, a phase three clinical trial sponsored by the National Eye Institute found. The trial, which included 691 patients or 854 eyes (as not everyone had both eyes treated), found that 3 to 4 percent of Lucentis-treated eyes had visual loss after the one year while 13 percent of those treated with lasers did, reports the New York Times. Lucentis is already approved for macular degeneration, and is similar to another Genentech drug, Avastin, which is approved for treating cancer and is more commonly prescribed off-label. Avastin, the Times notes, costs $20 to $100 a dose while Lucentis rings up at $2,000. However, the trial included Lucentis rather than Avastin since Roche (which now owns Genentech) said it would supply the drug for free as well as provide $9 million in financing for the trial if it were conducted on Lucentis.

Breaking News
The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.